Alzamend Neuro’s experimental oral therapy for dementia related to Alzheimer’s disease may deliver the benefits of marketed lithium-based treatments but with fewer side effects, data from a completed ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

A biomarker blood test called AlzoSure Predict that can help to identify people with mild cognitive impairment who are likely progress to Alzheimer’s disease — years before symptoms are evident — has ...

It took seven years from the time she started showing symptoms for Sophia Rodriguez’s mother to receive a confirmed diagnosis of Alzheimer’s disease. After her death 14 years later, Rodriguez can’t ...

When Lewis Hornby’s grandmother was rushed to the hospital in 2018, his family feared the worst. Pat Dickinson suffered from dementia, but in this instance it turned out that she was simply dehydrated ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Speaking more than one language appears to help the brain resist the effects of Alzheimer’s disease (AD), according to a study by Italy’s Vita-Salute San Rafffaele University in Milan. The study, “The ...

A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build up in the brain of those with Alzheimer’s — may have potential to treat and ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not it decided that aducanumab, an investigational treatment for Alzheimer’s disease developed by Biogen, ...

The PrecivityAD blood test from C2N Diagnostics significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for Alzheimer’s disease. C2N, which sponsored ...